Patents by Inventor Elliot Chartash

Elliot Chartash has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Treatment of spondyloarthropathies using TNFalpha inhibitors
    Publication number: 20070202104
    Abstract: Methods for treating spondyloarthropathies, including ankylosing spondylitis, using TNF? inhibitors are described.
    Type: Application
    Filed: July 18, 2003
    Publication date: August 30, 2007
    Applicant: Abbott Laboratories S.A.
    Inventors: Subhashis Banerjee, Lori Taylor, Clive Spiegler, Daniel Tracey, Elliot Chartash, Rebecca Hoffman, William Barchuk, Philip Yan, Anwar Murtaza, Jochen Salfeld, Steven Fischkoff
  • Treatment of respiratory syncytial virus (RSV) infection
    Publication number: 20060083741
    Abstract: The invention describes methods of treating and preventing respiratory syncytial virus (RSV) infection comprising administering a TNF inhibitor and an additional therapeutic agent. The invention also describes methods of treating and preventing respiratory syncytial virus (RSV) infection comprising administering an anti-TNF antibody and an anti-RSV antibody.
    Type: Application
    Filed: October 6, 2005
    Publication date: April 20, 2006
    Inventors: Rebecca Hoffman, Elliot Chartash, Paul Pollack
  • Multiple-variable dose regimen for treating TNFalpha-related disorders
    Publication number: 20060009385
    Abstract: Multiple-variable dose methods for treating TNF?-related disorders, including Crohn's disease and psoriasis, comprising administering TNF? inhibitors, including TNF? antibodies, are described. Multiple-variable dose methods include administration of a TNF-inhibitor in an induction or loading phase followed by administration of the agent in a maintenance or treatment phase, wherein the TNF-inhibitor is administered in a higher dosage during the induction phase.
    Type: Application
    Filed: April 11, 2005
    Publication date: January 12, 2006
    Applicant: Abbott Biotechnology Ltd.
    Inventors: Rebecca Hoffman, Elliot Chartash, Lori Taylor, George Granneman, Philip Yan
  • Use of anti-TNFalpha antibodies and another drug
    Publication number: 20040009172
    Abstract: The present invention is directed to a method of treating disorders in which TFN&agr; activity is detrimental via biweekly, subcutaneous administration of human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor &agr; (hTNF&agr;) in combination with another drug which is useful for treating the disorder. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Kits containing a pharmaceutical composition and instructions for dosing are also encompassed by the invention.
    Type: Application
    Filed: April 24, 2003
    Publication date: January 15, 2004
    Inventors: Steven Fischkoff, Elliot Chartash
  • Use of anti-TNFalpha antibodies and another drug
    Publication number: 20030206898
    Abstract: The present invention is directed to a method of treating disorders in which TFN&agr; activity is detrimental via biweekly, subcutaneous administration of human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor &agr; (hTNF&agr;) in combination with another drug which is useful for treating the disorder. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Kits containing a pharmaceutical composition and instructions for dosing are also encompassed by the invention.
    Type: Application
    Filed: April 26, 2002
    Publication date: November 6, 2003
    Inventors: Steven Fischkoff, Elliot Chartash